Palvella Therapeutics’ (PVLA) “Buy” Rating Reiterated at Chardan Capital

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $240.00 price objective on the stock. Chardan Capital’s price objective would indicate a potential upside of 110.33% from the company’s previous close.

Several other equities research analysts also recently weighed in on the company. Stephens started coverage on Palvella Therapeutics in a report on Tuesday, May 12th. They issued an “overweight” rating and a $220.00 price target for the company. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $114.11 on Thursday. The company has a market capitalization of $1.64 billion, a PE ratio of -27.36 and a beta of -0.13. The company has a 50-day simple moving average of $122.96 and a two-hundred day simple moving average of $105.14. Palvella Therapeutics has a one year low of $20.20 and a one year high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities analysts predict that Palvella Therapeutics will post -5.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Elaine J. Heron acquired 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The shares were bought at an average price of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. The trade was a 5.28% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Millennium Management LLC acquired a new stake in shares of Palvella Therapeutics during the 1st quarter worth approximately $7,553,000. Goldman Sachs Group Inc. acquired a new position in shares of Palvella Therapeutics in the 1st quarter valued at $533,000. Geode Capital Management LLC boosted its holdings in Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after buying an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, Rhumbline Advisers purchased a new position in Palvella Therapeutics in the second quarter valued at $224,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.